Ken Griffin Dr Reddys Laboratories LTD Call Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$75.41 - $84.21 $196,066 - $218,945	-2,600 Reduced 43.33%	3,400 $270,000
Q2 2024 Aug 14, 2024	BUY	$68.26 - $76.19 $20,478 - $22,857	300 Added 5.26%	6,000 $457,000
Q1 2024 May 15, 2024	BUY	$67.36 - $77.59 $181,872 - $209,493	2,700 Added 90.0%	5,700 $418,000
Q4 2023 Feb 14, 2024	BUY	$64.27 - $69.9 $19,281 - $20,970	300 Added 11.11%	3,000 $208,000
Q3 2023 Nov 14, 2023	BUY	$61.9 - $72.77 $123,800 - $145,540	2,000 Added 285.71%	2,700 $180,000
Q2 2023 Aug 14, 2023	SELL	$53.34 - $63.11 $106,680 - $126,220	-2,000 Reduced 74.07%	700 $44,000
Q1 2023 May 15, 2023	BUY	$51.63 - $56.93 $92,934 - $102,474	1,800 Added 200.0%	2,700 $153,000
Q4 2022 Feb 14, 2023	BUY	$51.15 - $57.45 $46,035 - $51,705	900 New	900 $46,000

242

23.2M

12.7K

6.1K

Ticker RDY
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 166,028,992
Market Cap $2.35B
Description
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), Proprietary Products, and Others segments. The company's Global Generics segment manufactures and markets prescription and over-t...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.